by David Wallace I got my first shot of Pegasys 3 days ago and local doc’s agreement to monitor my counts. It was not without a HARD push on my part as doc was still pushing the benefits of HU (hydroxyurea), while reinforcing the numerous risks with Peg, go figure. For once, I was glad […]
Pregnancy and Childbirth Outcomes in Women with MPNs
A Nationwide population-based study of 342 pregnancies in Sweden Abstract Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a large population-based study using Swedish health care registers, […]
MPN Awareness Day!
by David Wallace Today we celebrate MPN Awareness Day with our community! We are focused 24/7 on providing valuable resources to patients, caregivers and healthcare providers via our websites PV Reporter and MPN Cancer Connection. MPN Awareness and education is a daily practice rather than a special event. —> For myself personally, I take great […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]
Treatments for ET and PV Moving Towards Disease Modification
by Christina T. Loguidice, OncLive Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera. Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia (ET) […]
Can Polycythemia Vera Patients Live a Normal Lifespan?
by David Wallace Transcript | Can Polycythemia Vera (PV) Patients Live a Normal Lifespan? David Wallace: So you had several important abstracts and one that our listeners with PV will be excited about. So tell us about the potential for normal life expectancy in PV. Dr. Abu-Zeinah: So this a project was inspired by our […]
What is Blood Cancer?
Someone around the world is diagnosed with blood cancer every 35 seconds (every 3 minutes in the U.S.)… but what does this mean? With over 137 different types of blood cancer and blood disorders, it can be difficult to understand what exactly is meant by the term ‘blood cancer.’ This video uses a medical approach […]
Impact of Anti-Endothelial Cell Antibodies in Patients with Polycythemia Vera and Thrombosis
Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested. A new analysis of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera (PV) suggests that autoimmunity may be one mechanism by which thrombosis develops. Abstract Polycythemia vera (PV) causes thrombosis. Erythrocytosis and cell adhesiveness are responsible for thrombosis. JAK2V617F causes inflammation […]
Lifestyle, Environmental and Host Factors in the development of MPN
Abstract Philadelphia-negative myeloproliferative neoplasms (MPNs) occur when there is over-production of myeloid cells stemming from hematopoietic stem cells with constitutive activation of JAK/STAT signaling, with JAK2V617F being the most commonly occurring somatic driver mutation. Chronic inflammation is a hallmark feature of MPNs and it is now evident that inflammation is not only a symptom of MPN but […]
What constitutes disease modification in myelofibrosis?
Abstract The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what constitutes disease modification of myelofibrosis to advance appropriate drug […]
- 1
- 2
- 3
- …
- 17
- Next Page »
